Compare STKH & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKH | TCRT |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 8.1M |
| IPO Year | 2021 | N/A |
| Metric | STKH | TCRT |
|---|---|---|
| Price | $2.54 | $3.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 117.9K | 67.1K |
| Earning Date | 11-21-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,000.00 | $6,000.00 |
| Revenue This Year | N/A | $5,680,500.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.13 | $1.31 |
| 52 Week High | $72.80 | $6.20 |
| Indicator | STKH | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 48.37 |
| Support Level | $2.44 | $3.92 |
| Resistance Level | $4.09 | $4.50 |
| Average True Range (ATR) | 0.37 | 0.39 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 6.06 | 41.03 |
Steakholder Foods Ltd is engaged in transforming the alternative protein industries through its technology. The group specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These tools help manufacturers of all sizes efficiently produce foods that meet consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production. The company's expertise in creating alternative protein products replicating traditional meats' complex textures such as beef steaks, white fish, shrimp, and eel. It also explores the integration of cultivated cells, preparing for future advancements in food technology.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.